Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MacrogenicsFRA:M55 -2.16%50 3-Year EBITDA Growth Rate is 18.70% as of Jun. 2026, which is 46% above its 10-year median of 12.85. GuruFocus rates FRA:M55 with a GF Score™ of 50/100 and a GF Value™ of €3.24. The stock has 7 warning signs investors should review. Among 1,128 Biotechnology companies, Macrogenics ranks better than 54.52% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 18.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Macrogenics was 34.00% per year. The lowest was -93.70% per year. And the median was 12.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Macrogenics 3-Year EBITDA Growth Rate Related Terms
FRA:M55 vs WHWK, SRZN, SION: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Macrogenics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Macrogenics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 18.70% mean?
Macrogenics (FRA:M55) has a 3-Year EBITDA Growth Rate of 18.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Macrogenics and its competitors. This is 46% above median its historical median of 12.85. According to the industry distribution chart, Macrogenics ranks #513 out of 1128 companies in the Biotechnology industry, placing it in the top 45.5%.
Is Macrogenics' 3-Year EBITDA Growth Rate too high?
Macrogenics' current 3-Year EBITDA Growth Rate of 18.70% is 46% above median its 10-year median of 12.85. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Macrogenics' value of 18.70% is 27.6% above this industry median. Based on the distribution chart, Macrogenics ranks #513 out of 1128 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Macrogenics has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' 3-Year EBITDA Growth Rate compare to WHWK and SRZN?
According to the Biotechnology industry distribution chart, Macrogenics ranks #513 out of 1128 companies for 3-Year EBITDA Growth Rate. This puts Macrogenics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. Macrogenics' value of 18.70% is 27.6% above this benchmark. While the company's 10-year median is 12.85 vs. the industry median of 14.65, Macrogenics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Macrogenics's current 3-Year EBITDA Growth Rate of 18.70% is 27.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Macrogenics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macrogenics's current 3-Year EBITDA Growth Rate is 18.70%, which is 46% above median its own 10-year median of 12.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Macrogenics (FRA:M55) has a current 3-Year EBITDA Growth Rate of 18.70%. The stock's GF Value™ is €3.24, compared to a current price of €3.62 — trading 11.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 18.70%, which is 46% above median its 10-year median of 12.85 and 27.6% above the Biotechnology industry median of 14.65. Macrogenics' overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current 3-Year EBITDA Growth Rate is 18.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (FRA:M55) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued.
The current stock price of €3.62 is trading 11.7% above its estimated GF Value™ of €3.24.
Key valuation signals for FRA:M55:
3-Year EBITDA Growth Rate: 18.70% (46% above median its 10-year median of 12.85)
GF Value™: €3.24 vs. price of €3.62 (11.7% above fair value)
Industry Position: 27.6% above the Biotechnology median (#513 of 1128)
No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
50GF Score
Get the complete analysis for FRA:M55
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M55 has been successfully added to your 
